Pharmaceuticals, Biotechnology and Life Sciences
DiscGenics’s IDCT cell therapy has passed the initial planned safety review of its Phase I/II trial evaluating the allogeneic, injectable disc cell therapy in patients with mild to moderate degenerative disc disease (DDD).
A UK- and Austria-based Biotech company F2G Ltd, has raised funding from life science investor Morningside Venture Investments Ltd. (Morningside), after borrowing €24 million from the European Investment Bank (EIB) in November 2018 to speed up the phase 2 study for its lead candidate, a treatment for invasive fungal infections, olorofim.
Catalyst Pharmaceuticals Phase IIb clinical trial for Firdapse tablets, published in SAGE Open Medicine, for the treatment of MuSK antibody positive Myasthenia Gravis (MuSK-MG), has given evidence that amifampridine phosphate was safe and effective in treating MuSK-MG patients.
BerGenBio ASA has been dosed the first patient with bemcentinib, in an investigator-initiated phase II trial, sponsored by GWT-TUD GmbH, a specialist cancer clinical research institution associated with the University of Dresden, Germany.
ADC Therapeutics, an oncology drug discovery and development company, has dosed first patient in its Phase Ib clinical trial of ADCT-301 in patients with selected solid tumors that are locally advanced or metastatic.
Novavax reported Friday that the Phase 2 clinical trial found all formulations of NanoFlu were well-tolerated and elicited vigorous immune responses to the four strains included in the vaccine.
Maker of fibrosis therapeutics, Promedior, said has agreed with the U.S. Food and Drug Administration (FDA) for registration, on the design of the study of PRM-151, a novel investigational anti-fibrotic immunomodulator, in patients with Idiopathic Pulmonary Fibrosis (IPF).
Copenhagen-based biotechnology company Zealand Pharma focused on peptide-based drugs,has completed a $5 million equity investment in Beta Bionics, a medical technology company developing the iLet bionic pancreas system.
Basilea Pharmaceutica’s CEO David Veitch, will present at the 37th Annual J. P. Morgan Healthcare Conference on January 10, 2019, where he’ll describe both the progress made during 2018 and the priorities for 2019 to deliver on the key elements of Basilea’s strategy for continued value creation, the company said Friday.
MatriSys Bioscience is waiting to meet with the US FDA to complete preparations for its company-sponsored Phase 2 trial of its anti-atopic dermatitis topical drug candidate, MSB-01, it said Wednesday.